A look at big oncology deals since 2016 suggests that there have been more duds than successes.

Lifileucel heads up the list of upcoming US FDA catalysts.

Private company trial initiations stand out in the latest week’s disclosures.

A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.

Despite magrolimab’s latest flop, efforts to target CD47 continue.